ArticleBMC cancer2026
Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite significant advances in systemic therapies, non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs) have improved outcomes in advanced disease, durable responses occur in only a subset of patients. Radiotherapy (RT) may enhance antitumor immunity by modulating the tumor microenvironment. This study aimed to evaluate the association between RT and survival outcomes in patients with advanced NSCLC treated with nivolumab.
methodsThis retrospective study included patients with advanced NSCLC who progressed after first-line platinum-based chemotherapy and received nivolumab as second-line therapy between January 2015 and January 2025. Patients who received RT before or during nivolumab, including RT for oligoprogression, were evaluated. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates and Cox regression models.
resultsA total of 191 patients were included. The median age was 64 years (range, 37–83), and adenocarcinoma and squamous cell carcinoma accounted for 47.6% and 44% of cases, respectively. Median PFS and OS were 6.9 and 14.1 months, respectively. Patients who received RT had significantly longer PFS (11.9 vs. 3.6 months; p < 0.001) and OS (31.8 vs. 8.3 months; p < 0.001) compared with those who did not. Median PFS was not reached in patients receiving RT for oligoprogression, with 57% remaining progression-free at 6 months. Multivariate analysis identified ECOG performance status, RT history, and adrenal metastases as independent predictors of PFS, while ECOG performance status, prior surgery, RT history, and brain and adrenal metastases were independent predictors of OS.
conclusionsRT administered before or during nivolumab was associated with improved survival outcomes in advanced NSCLC. However, given the retrospective design and potential selection bias, these findings should be interpreted cautiously. Prospective studies are needed to clarify the optimal integration and timing of RT with ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.